Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleFEATURED CLINICAL INVESTIGATION ARTICLE
Open Access

Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer

Lisa M. Gudenkauf, Melody N. Chavez, Melinda Leigh Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha I. Hoogland, Kathleen Nguyen, Vishnu Murthy, Wesley R. Armstrong, Khaled Komrokji, Laura B. Oswald, Heather S.L. Jim, Ghassan El-Haddad, Wolfgang P. Fendler, Ken Herrmann, David Cella, Johannes Czernin, Michael S. Hofman, Adam P. Dicker, Jeremie Calais, Scott T. Tagawa and Brian D. Gonzalez
Journal of Nuclear Medicine June 2023, 64 (6) 869-872; DOI: https://doi.org/10.2967/jnumed.122.264946
Lisa M. Gudenkauf
1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melody N. Chavez
2Participant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melinda Leigh Maconi
2Participant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carley Geiss
2Participant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ameen Seyedroudbari
3Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pan Thin
3Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aasha I. Hoogland
1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen Nguyen
3Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vishnu Murthy
3Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wesley R. Armstrong
3Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khaled Komrokji
1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura B. Oswald
1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather S.L. Jim
1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ghassan El-Haddad
4Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang P. Fendler
5Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium–University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Herrmann
5Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium–University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Cella
6Departments of Medical Social Sciences and Psychiatry and Behavioral Sciences, and Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Czernin
3Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael S. Hofman
7Prostate Cancer Theranostics and Imaging Centre of Excellence, Cancer Imaging, Peter MacCallum Centre, Melbourne, Victoria, Australia, and MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam P. Dicker
8Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Cancer, Thomas Jefferson University, Woodbury, New Jersey; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremie Calais
3Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott T. Tagawa
9Department of Urology, Weill Cornell Medical College, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian D. Gonzalez
1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Visual Abstract

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first 177Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patients receiving RNT. Methods: We identified relevant symptoms and toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the Functional Assessment of Cancer Therapy–Radionuclide Therapy (FACT-RNT) with patient input. Results: This multistep process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The FACT-RNT is a new standardized tool to monitor relevant symptoms and toxicities among PC patients in RNT trials and real-world settings.

  • genitourinary oncology
  • radionuclide therapy
  • radiopharmaceuticals
  • patient-reported outcomes
  • prostate cancer
  • radionuclide therapy

Footnotes

  • Published online Jan. 12, 2023.

  • © 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

View Full Text
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (6)
Journal of Nuclear Medicine
Vol. 64, Issue 6
June 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
Lisa M. Gudenkauf, Melody N. Chavez, Melinda Leigh Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha I. Hoogland, Kathleen Nguyen, Vishnu Murthy, Wesley R. Armstrong, Khaled Komrokji, Laura B. Oswald, Heather S.L. Jim, Ghassan El-Haddad, Wolfgang P. Fendler, Ken Herrmann, David Cella, Johannes Czernin, Michael S. Hofman, Adam P. Dicker, Jeremie Calais, Scott T. Tagawa, Brian D. Gonzalez
Journal of Nuclear Medicine Jun 2023, 64 (6) 869-872; DOI: 10.2967/jnumed.122.264946

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
Lisa M. Gudenkauf, Melody N. Chavez, Melinda Leigh Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha I. Hoogland, Kathleen Nguyen, Vishnu Murthy, Wesley R. Armstrong, Khaled Komrokji, Laura B. Oswald, Heather S.L. Jim, Ghassan El-Haddad, Wolfgang P. Fendler, Ken Herrmann, David Cella, Johannes Czernin, Michael S. Hofman, Adam P. Dicker, Jeremie Calais, Scott T. Tagawa, Brian D. Gonzalez
Journal of Nuclear Medicine Jun 2023, 64 (6) 869-872; DOI: 10.2967/jnumed.122.264946
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy
  • Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T
  • Google Scholar

More in this TOC Section

  • 177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial
  • Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories
  • PET Quantification in Healthy Humans of Cyclooxygenase-2, a Potential Biomarker of Neuroinflammation
Show more FEATURED CLINICAL INVESTIGATION ARTICLE

Similar Articles

Keywords

  • genitourinary oncology
  • radionuclide therapy
  • radiopharmaceuticals
  • patient-reported outcomes
  • prostate cancer
SNMMI

© 2025 SNMMI

Powered by HighWire